Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Diabetes

Free Subscription Articles published in Ann Intern Med Retrieve available abstracts of 101 articles: HTML format

Single Articles

July 2026
1. LIPSKA KJ, Zawack K, Yan L, Mutalik P, et al
   Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.
   Ann Intern Med. 2026 Jul 14. doi: 10.7326/ANNALS-25-05216.
   PubMed     Abstract available
   
   
   June 2026
2. ARTERBURN D, Curtis LH, Toh S, Bradley MC, et al
   Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-25-05468.
   PubMed     Abstract available
   
   
   
3. CURTIS LH, Arterburn D, Toh S, Guo J, et al
   Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00202.
   PubMed     Abstract available
   
   
   
4. LIU M, Cheng Z, Lu L, Cai H, et al
   Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-25-04623.
   PubMed     Abstract available
   
   
   
5. LAU D
   In T2D inadequately controlled with metformin, orforglipron reduced HbA(1c) more than oral semaglutide at 52 wk.
   Ann Intern Med. 2026;179:JC62.
   PubMed     Abstract available
   
   
   May 2026
6. DEL PRATO S, Heine RJ, Perez Manghi FC, Hsia SH, et al
   Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial.
   Ann Intern Med. 2026 May 26. doi: 10.7326/ANNALS-25-05602.
   PubMed     Abstract available
   
   
   
7. KARAGIANNIS T, Avgerinos I, Tsapas A
   In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.
   Ann Intern Med. 2026;179:JC53.
   PubMed     Abstract available
   
   
   
8. ESCUDERO C, Havranek K, Martinez Cruz M, Batch B, et al
   Endocrinology: What You May Have Missed in 2025.
   Ann Intern Med. 2026;179.
   PubMed     Abstract available
   
   
   April 2026
9. 
   Correction: Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes.
   Ann Intern Med. 2026 Apr 21. doi: 10.7326/ANNALS-26-01314.
   PubMed    
   
   
   
10. DIEMER M
    In patients with painful diabetic neuropathy, pregabalin does not differ from duloxetine for pain.
    Ann Intern Med. 2026 Apr 7. doi: 10.7326/ANNALS-26-00955.
    PubMed     Abstract available
    
    
    
11. MCDONNELL DJ, Dinneen SF
    In adults with T1D and overweight or obesity, adding GLP-1 RAs to insulin reduces weight, HbA(1c) levels, and insulin dose.
    Ann Intern Med. 2026;179:JC44.
    PubMed     Abstract available
    
    
    March 2026
12. BOYE KS, Sharma P, Chivukula KK, Farrell EB, et al
    Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide.
    Ann Intern Med. 2026 Mar 31. doi: 10.7326/ANNALS-25-03219.
    PubMed    
    
    
    
13. KANAYA AM, Gadgil MD
    In adults with prediabetes and overweight or obesity, an AI- vs. human-led lifestyle intervention was noninferior for a composite outcome at 12 mo.
    Ann Intern Med. 2026;179:JC34.
    PubMed     Abstract available
    
    
    February 2026
14. KO A, Chang YC, Bahar F, Wang TH, et al
    Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.
    Ann Intern Med. 2026;179:216-229.
    PubMed     Abstract available
    
    
    January 2026
15. PATTI ME, Hu B, Kirschling S, Wang HJ, et al
    Effect of Social Vulnerability on Efficacy of Bariatric Surgery Versus Medical and Lifestyle Intervention for Type 2 Diabetes: Analysis of the ARMMS-T2D Consortium of Randomized Trials.
    Ann Intern Med. 2026 Jan 20. doi: 10.7326/ANNALS-24-01882.
    PubMed     Abstract available
    
    
    
16. 
    Correction: Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes.
    Ann Intern Med. 2026 Jan 13. doi: 10.7326/ANNALS-25-04192.
    PubMed    
    
    
    
17. KRISTENSEN FPB, Christensen DH, Callaghan BC, Nielsen JS, et al
    Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists on Diabetic Foot Disease : An Emulated Target Trial.
    Ann Intern Med. 2026 Jan 6. doi: 10.7326/ANNALS-25-01262.
    PubMed     Abstract available
    
    
    December 2025
18. YAN VKC, Blais JE, Gamble JM, Chan EWY, et al
    Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk : A Target Trial Emulation Study.
    Ann Intern Med. 2025 Dec 30. doi: 10.7326/ANNALS-25-00662.
    PubMed     Abstract available
    
    
    
19. LIBMAN H, LaSalvia MT, Rosenblum BI, Reynolds EE, et al
    How Would You Manage This Diabetic Patient With a Foot Infection? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2025 Dec 9. doi: 10.7326/ANNALS-25-04326.
    PubMed     Abstract available
    
    
    November 2025
20. LESSER LI
    In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.
    Ann Intern Med. 2025 Nov 4. doi: 10.7326/ANNALS-25-04321.
    PubMed     Abstract available
    
    
    
21. CRISAFULLI S, Alkabbani W, Paik JM, Bykov K, et al
    Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.
    Ann Intern Med. 2025 Nov 4. doi: 10.7326/ANNALS-25-01724.
    PubMed     Abstract available
    
    
    
22. HEERSPINK HJL, Grams ME, Sang Y, Ballew SH, et al
    Proteinuria or Albuminuria as Markers of Kidney and Cardiovascular Disease Risk : An Individual Patient-Level Meta-analysis.
    Ann Intern Med. 2025 Nov 4. doi: 10.7326/ANNALS-25-02117.
    PubMed     Abstract available
    
    
    October 2025
23. SHAHID M, Gandhi GY
    In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA(1c) vs. placebo at 40 wk.
    Ann Intern Med. 2025;178:JC114.
    PubMed     Abstract available
    
    
    
24. TANNER M
    In insulin-naive T2D, fixed-dose weekly efsitora was noninferior to daily glargine for reducing HbA(1c) at 52 wk.
    Ann Intern Med. 2025;178:JC113.
    PubMed     Abstract available
    
    
    
25. LAU D, Padwal R
    In T2D and hypertension, the lower-sodium DASH4D diet reduced SBP more than a higher-sodium comparison diet at 5 wk.
    Ann Intern Med. 2025;178:JC115.
    PubMed     Abstract available
    
    
    September 2025
26. JUNG M, Reisert M, Rieder H, Rospleszcz S, et al
    Association Between Body Composition and Cardiometabolic Outcomes : A Prospective Cohort Study.
    Ann Intern Med. 2025 Sep 30. doi: 10.7326/ANNALS-24-01863.
    PubMed     Abstract available
    
    
    
27. WEITZ HH, Merli GJ
    Annals Consult Guys - Diabetes Issues in Ambulatory Surgery.
    Ann Intern Med. 2025;178:e2504052CG.
    PubMed    
    
    
    
28. ADES M, Anand SS
    In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y.
    Ann Intern Med. 2025;178:JC100.
    PubMed     Abstract available
    
    
    August 2025
29. RUIZ-CANELA M, Corella D, Martinez-Gonzalez MA, Babio N, et al
    Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes : A Secondary Analysis of a Randomized Controlled Trial.
    Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-00388.
    PubMed     Abstract available
    
    
    
30. 
    Summary for Patients: Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes.
    Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-00388.
    PubMed    
    
    
    
31. HERRING SJ, Tripicchio GL
    Reducing Diabetes Risk Through the Mediterranean Diet.
    Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-02748.
    PubMed    
    
    
    
32. NADGIR U, Ali SR, Gogate J, Shaw W, et al
    Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial.
    Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-24-04017.
    PubMed     Abstract available
    
    
    
33. 
    Summary for Patients: Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes.
    Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-24-04017.
    PubMed    
    
    
    
34. CENTOR RM, Billings LK
    Annals On Call - Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control Is Inadequate With Dulaglutide.
    Ann Intern Med. 2025 Aug 5:e2503404OC. doi: 10.7326/ANNALS-25-03404.
    PubMed    
    
    
    
35. BRADY RP, Shah AS
    Expanding the Treatment Vault: Canagliflozin in Youth With Type 2 Diabetes.
    Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-25-02805.
    PubMed    
    
    
    
36. CENTOR RM, Kip K, Saeed A
    Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.
    Ann Intern Med. 2025;178:e2503594OC.
    PubMed    
    
    
    
37. LAU D, Senior P
    In insulin-treated T2D, automated insulin delivery reduced HbA(1c) without increasing hypoglycemic events vs. usual care at 13 wk.
    Ann Intern Med. 2025;178:JC95.
    PubMed     Abstract available
    
    
    July 2025
38. PLASCENCIA-VILLA G, Xu R, Perry G
    Potential Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Diabetes and High Risk for Dementia.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-02362.
    PubMed    
    
    
    
39. WU Z, Sheng C, Guo Z, Zheng Y, et al
    Association of Weekend Warrior and Other Physical Activity Patterns With Mortality Among Adults With Diabetes : A Cohort Study.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-00640.
    PubMed     Abstract available
    
    
    
40. SIGAL RJ, Boule NG
    Physical Activity in Type 2 Diabetes: Could One or Two Weekly Sessions Be Enough?
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-02522.
    PubMed    
    
    
    
41. INOUE K, Saliba D, Gotanda H, Moin T, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes : A Target Trial Emulation.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-24-02648.
    PubMed     Abstract available
    
    
    
42. NOH Y, Yin H, Yu OHY, Bitton A, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.
    Ann Intern Med. 2025 Jul 15. doi: 10.7326/ANNALS-24-03420.
    PubMed     Abstract available
    
    
    
43. BANDI SSS, Montori VM
    In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.
    Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-02173.
    PubMed     Abstract available
    
    
    
44. SHAHID M, Gandhi GY
    In patients with diabetes and previous MI, high-dose multivitamins and minerals did not reduce CV events.
    Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-02174.
    PubMed     Abstract available
    
    
    June 2025
45. SAEED A, Mulukutla SR, Thoma F, Lemon L, et al
    Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.
    Ann Intern Med. 2025 Jun 17. doi: 10.7326/ANNALS-24-00775.
    PubMed     Abstract available
    
    
    
46. 
    Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.
    Ann Intern Med. 2025 Jun 17. doi: 10.7326/ANNALS-24-00775.
    PubMed    
    
    
    
47. CENTOR RM, Moiz A
    Annals On Call - Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in the Absence of Diabetes.
    Ann Intern Med. 2025 Jun 3:e2502205OC. doi: 10.7326/ANNALS-25-02205.
    PubMed    
    
    
    
48. THAKKAR A, Newby LK
    In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo.
    Ann Intern Med. 2025 Jun 3. doi: 10.7326/ANNALS-25-01791.
    PubMed     Abstract available
    
    
    May 2025
49. QASEEM A, Basch P, Campos K, MacDonald ST, et al
    Quality Indicators for Diabetes in Adults: A Review of Performance Measures by the American College of Physicians.
    Ann Intern Med. 2025 May 6. doi: 10.7326/ANNALS-24-03770.
    PubMed     Abstract available
    
    
    
50. LAU D
    In adults with overweight or obesity and without diabetes, GLP-1 RAs increase weight loss vs. placebo.
    Ann Intern Med. 2025 May 6. doi: 10.7326/ANNALS-25-01325.
    PubMed     Abstract available
    
    
    
51. OSTROMINSKI JW, Ortega-Montiel J, Tesfaye H, Alix C, et al
    Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study.
    Ann Intern Med. 2025;178:620-633.
    PubMed     Abstract available
    
    
    April 2025
52. MAKAM AN, Bailey L, Anderson N, Bellitti K, et al
    Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program.
    Ann Intern Med. 2025 Apr 22. doi: 10.7326/ANNALS-24-01449.
    PubMed     Abstract available
    
    
    
53. BILLINGS LK, Winne L, Sharma P, Gomez-Valderas E, et al
    Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
    Ann Intern Med. 2025 Apr 4. doi: 10.7326/ANNALS-24-03849.
    PubMed     Abstract available
    
    
    
54. 
    Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide.
    Ann Intern Med. 2025 Apr 4. doi: 10.7326/ANNALS-24-03849.
    PubMed    
    
    
    
55. SHADBOLT C, Elkin J, Schilling C, Hua X, et al
    National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults Without Diabetes, 2018 to 2022.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-24-02878.
    PubMed    
    
    
    
56. CENTOR RM, Maciejewski ML, Sloan C
    Annals On Call - Health Expenditures of Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2025;178:e2501511OC.
    PubMed    
    
    
    
57. AMAN M, Jeevananthan A, Martinez-Cruz M, Namasingh N, et al
    Endocrinology: What You May Have Missed in 2024.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00990.
    PubMed     Abstract available
    
    
    March 2025
58. OSERAN AS, Aggarwal R, Figueroa J, Joynt Maddox KE, et al
    Prevalence of Chronic Medical Conditions Among Medicare Advantage and Traditional Medicare Beneficiaries.
    Ann Intern Med. 2025;178:327-335.
    PubMed     Abstract available
    
    
    February 2025
59. TANG H, Lu Y, Donahoo WT, Westen SC, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Ann Intern Med. 2025 Feb 25. doi: 10.7326/ANNALS-24-01347.
    PubMed     Abstract available
    
    
    January 2025
60. MACIEJEWSKI ML, Zepel L, Smith VA, Arterburn DE, et al
    Health Expenditures of Patients With Diabetes After Bariatric Surgery: Comparing Gastric Bypass and Sleeve Gastrectomy.
    Ann Intern Med. 2025 Jan 28. doi: 10.7326/ANNALS-24-00480.
    PubMed     Abstract available
    
    
    
61. 
    Annals Video Summary - Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
    Ann Intern Med. 2025 Jan 7:e2403525VS. doi: 10.7326/ANNALS-24-03525.
    PubMed    
    
    
    
62. 
    Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
    Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
    PubMed    
    
    
    
63. MOIZ A, Filion KB, Toutounchi H, Tsoukas MA, et al
    Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
    Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
    PubMed     Abstract available
    
    
    
64. LARIOS F, Gionfriddo MR, Montori VM
    In T1D, weekly efsitora was noninferior to daily degludec for reducing HbA(1c) but increased severe hypoglycemia at 26 wk.
    Ann Intern Med. 2025;178:JC11.
    PubMed     Abstract available
    
    
    
65. LARIOS F, Gionfriddo MR, Montori VM
    In insulin-naive T2D, weekly efsitora was noninferior to daily degludec for reducing HbA(1c) at 52 wk.
    Ann Intern Med. 2025;178:JC10.
    PubMed     Abstract available
    
    
    December 2024
66. VASSILOPOULOS S, Mylonakis E
    After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
    Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
    PubMed     Abstract available
    
    
    
67. GIANCHANDANI R, Wei M, Demidowich A
    Management of Hyperglycemia in Hospitalized Patients.
    Ann Intern Med. 2024;177:ITC177-ITC192.
    PubMed     Abstract available
    
    
    November 2024
68. ZHU D, Herrington WG
    In adults with BMI >/=27 kg/m(2) and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA(1c) level.
    Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02457.
    PubMed     Abstract available
    
    
    
69. MAHER M, Dinneen S
    In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.
    Ann Intern Med. 2024;177:JC124.
    PubMed     Abstract available
    
    
    
70. ZHU D, Herrington WG
    In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
    Ann Intern Med. 2024;177:JC123.
    PubMed     Abstract available
    
    
    October 2024
71. FITCH KV, Zanni MV, Manne-Goehler J, Diggs MR, et al
    Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.
    Ann Intern Med. 2024 Oct 8. doi: 10.7326/ANNALS-24-00944.
    PubMed     Abstract available
    
    
    
72. HONG B, Bea S, Ko HY, Kim WJ, et al
    Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study.
    Ann Intern Med. 2024;177:1319-1329.
    PubMed     Abstract available
    
    
    September 2024
73. COLLISTER D, Pannu N
    In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
    Ann Intern Med. 2024;177:JC98.
    PubMed     Abstract available
    
    
    
74. YEO YH, Rezaie A, Hsieh TY, Hu X, et al
    Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis.
    Ann Intern Med. 2024;177:1289-1291.
    PubMed    
    
    
    August 2024
75. CHAITOFF A, Bendicksen L, Feldman WB, Zheutlin AR, et al
    Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.
    Ann Intern Med. 2024 Aug 27. doi: 10.7326/ANNALS-24-00308.
    PubMed    
    
    
    
76. KANJEE Z, Brown FM, Taxin ZH, Smetana GW, et al
    How Would You Treat This Inpatient With Type 2 Diabetes Mellitus? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Aug 13. doi: 10.7326/ANNALS-24-01100.
    PubMed     Abstract available
    
    
    July 2024
77. WANG W, Volkow ND, Berger NA, Davis PB, et al
    Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
    Ann Intern Med. 2024 Jul 30. doi: 10.7326/M23-2718.
    PubMed     Abstract available
    
    
    
78. TANG H, Lu Y, Donahoo WT, Shao H, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/M24-0329.
    PubMed     Abstract available
    
    
    
79. 
    Summary for Patients: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/P24-0004.
    PubMed    
    
    
    
80. CENTOR RM, Crandall CJ
    Annals On Call - ACP Recommendation: Pharmacologic Treatment of Type 2 Diabetes.
    Ann Intern Med. 2024;177:e2401521OC.
    PubMed    
    
    
    
81. TANNER M
    In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortality.
    Ann Intern Med. 2024;177:JC83.
    PubMed     Abstract available
    
    
    
82. CHIU YH, Huybrechts KF, Patorno E, Yland JJ, et al
    Metformin Use in the First Trimester of Pregnancy and Risk for Nonlive Birth and Congenital Malformations: Emulating a Target Trial Using Real-World Data.
    Ann Intern Med. 2024;177:862-870.
    PubMed     Abstract available
    
    
    June 2024
83. CRAWFORD AL, Laiteerapong N
    Type 2 Diabetes.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/AITC202406180.
    PubMed     Abstract available
    
    
    
84. SMETANA GW, Romeo GR, Rosas SE, Burns RB, et al
    How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/M24-0764.
    PubMed     Abstract available
    
    
    May 2024
85. LAINE C, Moyer DV, Qaseem A
    Newer Pharmacologic Treatments for Type 2 Diabetes.
    Ann Intern Med. 2024 May 28. doi: 10.7326/ANNALS-24-00698.
    PubMed    
    
    
    
86. O'BRIEN C, Dinneen SF
    In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0028.
    PubMed     Abstract available
    
    
    
87. BATES ER
    In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026.
    PubMed     Abstract available
    
    
    
88. MARUTHUR NM, Pilla SJ, White K, Wu B, et al
    Effect of Isocaloric, Time-Restricted Eating on Body Weight in Adults With Obesity : A Randomized Controlled Trial.
    Ann Intern Med. 2024;177:549-558.
    PubMed     Abstract available
    
    
    April 2024
89. YEN FS, Hwu CM, Liu JS, Wu YL, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Ann Intern Med. 2024 Apr 30. doi: 10.7326/M23-1874.
    PubMed     Abstract available
    
    
    
90. DRAKE T, Landsteiner A, Langsetmo L, MacDonald R, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1490.
    PubMed     Abstract available
    
    
    
91. SCHOUSBOE JT, Landsteiner A, Drake T, Sultan S, et al
    Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1492.
    PubMed     Abstract available
    
    
    
92. QASEEM A, Obley AJ, Shamliyan T, Hicks LA, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-2788.
    PubMed     Abstract available
    
    
    
93. SYED FZ
    Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M24-0861.
    PubMed    
    
    
    
94. 
    Annals Video Summary - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Apr 19:eM231554. doi: 10.7326/M23-1554.
    PubMed    
    
    
    
95. 
    Visual Guideline - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Visual Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19:eM240803. doi: 10.7326/M24-0803.
    PubMed     Abstract available
    
    
    
96. KELSEY M, Newby LK
    In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.
    Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0016.
    PubMed     Abstract available
    
    
    
97. HWANG JH, Hsu CY
    In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.
    Ann Intern Med. 2024;177:JC40.
    PubMed     Abstract available
    
    
    
98. EGAN AM
    In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin.
    Ann Intern Med. 2024;177:JC47.
    PubMed     Abstract available
    
    
    March 2024
99. GARABEDIAN LF, Zhang F, Costa R, Argetsinger S, et al
    Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
    Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-1965.
    PubMed     Abstract available
    
    
    
100. KOUTROUMPAKIS E, Deswal A
     In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
     Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0008.
     PubMed     Abstract available
     
     
     
101. PERSELL SD, Petito LC, Lee JY, Meeker D, et al
     Reducing Care Overuse in Older Patients Using Professional Norms and Accountability : A Cluster Randomized Controlled Trial.
     Ann Intern Med. 2024;177:324-334.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum